Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allergan 'Unusual Suspect' But Pipeline 'Hunger' A Perfect Match For Heptares

This article was originally published in Scrip

Executive Summary

With Scrip still reeling from the news earlier this week that Pfizer and Allergan have called off their $160bn mega-merger, news broke that former darling of the UK biotech scene Heptares, now a wholly-owned subsidiary and the 'R&D engine' of Japanese company Sosei Group Corp., has secured a notable licensing deal with Allergan. Scrip caught up with Heptares CEO Malcolm Weir to get his take on the fall of PfizerGan (PfAllergan?), and of course the small matter of securing a partnership deal worth up to $3.34bn plus potential royalties.

You may also be interested in...



Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion

Japan-based Sosei's recent equity offering made its shareholder base more international and will help finance the evolution of the group's proprietary pipeline.

Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

CNS Licensing Trends: Volume Falls, Values Rise

According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC032210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel